Sanofi

CIK 0001121404 · PARIS, I0 · Quarter end: 2026-06-30 · Filed on: 2026-07-28 · Open the SEC source

Sanofi reported 10 positions worth $534.0M as of June 30, 2026 (13F filed July 28, 2026). Largest holding: MGTX (30.9%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$534.0M
2026 Q2
Positions
10
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
100.0%
Est. Net Flow (Q)
2026 Q2
10 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1MGTXMeiraGTx Holdings plcSH$164.8M30.86%12,197,737
2INBXInhibrx Biosciences, Inc.SH$109.7M20.54%1,157,926
3NVAXNovavaxSH$64.8M12.14%6,880,481
4ANABAnaptysBio SH$55.5M10.39%821,917
5ODTXOdyssey Therapeutics Inc.SH$37.3M6.98%1,991,918
6AGMBAgomab Therapeutics NVSH$36.1M6.76%2,783,096
7MPLTMapLight Therapeutics Inc.SH$32.7M6.12%912,041
8TRAXFirst Tracks Biotherapeutics Inc.SH$16.5M3.10%821,917
9IMRXImmuneering CorpSH$13.5M2.53%2,708,559
10QTTBQ32 Bio Inc.SH$3.1M0.58%244,083

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Sanofi hold as of Q2 2026?

Sanofi reported 10 positions worth $534.0M in its Q2 2026 13F filing. Largest positions: MGTX (30.9%), INBX (20.5%), NVAX (12.1%), ANAB (10.4%) and ODTX (7.0%).

What did Sanofi buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Sanofi sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.